ADC Therapeutics has reported positive results from the Phase II clinical trial of loncastuximab tesirine (ADCT-402) for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Loncastuximab tesirine is an antibody drug conjugate (ADC) that includes a humanised monoclonal antibody. It is engineered to target the CD19-expressing cell, highly expressed in a range of B-cell hematological tumours including lymphoma.

The single-arm, multi-centre, open-label Phase II clinical trial aimed to test the efficacy, safety and pharmacokinetics of the candidate as a monotherapy in patients with relapsed or refractory DLBCL.

The study involved 145 patients administered with 30-minute intravenous infusions of loncastuximab tesirine once every three weeks.

The dose was fixed at 150μg/kg for the first two three-week cycles, followed by 75μg/kg in subsequent cycles until discontinuation.

Loncastuximab tesirine achieved an overall response rate (ORR) of 45.5%. In Phase I trials, the candidate demonstrated an ORR of 41.4% at the initial dose used in Phase II.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADC Therapeutics senior vice-president and chief medical officer Jay Feingold said: “These data exceeded our primary endpoint target and reinforce the significant single-agent anti-tumour activity and manageable toxicity profile of loncastuximab tesirine in patients with relapsed or refractory DLBCL who have failed established therapies.

“Loncastuximab tesirine has demonstrated its potential to fill a critical unmet need for a new therapy and become a key part of the treatment paradigm for all heavily pretreated patients with DLBCL.

“We plan to present final data from the pivotal Phase II clinical trial at a future scientific meeting.”